Zacks: Analysts Expect Nautilus Biotechnology, Inc. (NASDAQ:NAUT) to Post -$0.17 EPS

Analysts expect Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) to post ($0.17) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for Nautilus Biotechnology’s earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.15). Nautilus Biotechnology reported earnings of ($0.19) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 10.5%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Nautilus Biotechnology.

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) last released its quarterly earnings results on Thursday, February 24th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02.

A number of research firms recently weighed in on NAUT. The Goldman Sachs Group dropped their price target on shares of Nautilus Biotechnology from $9.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 13th. Zacks Investment Research lowered shares of Nautilus Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, April 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Nautilus Biotechnology presently has a consensus rating of “Hold” and an average target price of $8.67.

NAUT opened at $3.85 on Wednesday. The company’s 50-day moving average is $4.12 and its 200 day moving average is $4.46. Nautilus Biotechnology has a fifty-two week low of $3.13 and a fifty-two week high of $12.38. The firm has a market capitalization of $479.18 million and a P/E ratio of -6.75.

In related news, CEO Sujal M. Patel acquired 50,000 shares of the stock in a transaction on Monday, May 9th. The shares were acquired at an average price of $3.96 per share, with a total value of $198,000.00. Following the completion of the transaction, the chief executive officer now owns 9,964,488 shares in the company, valued at approximately $39,459,372.48. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Raymond James & Associates increased its stake in shares of Nautilus Biotechnology by 18.0% in the third quarter. Raymond James & Associates now owns 18,797 shares of the company’s stock worth $115,000 after purchasing an additional 2,863 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Nautilus Biotechnology by 35.1% in the first quarter. JPMorgan Chase & Co. now owns 14,783 shares of the company’s stock worth $64,000 after purchasing an additional 3,837 shares in the last quarter. Citigroup Inc. increased its stake in shares of Nautilus Biotechnology by 130.3% in the first quarter. Citigroup Inc. now owns 10,387 shares of the company’s stock worth $45,000 after purchasing an additional 5,877 shares in the last quarter. State Street Corp increased its stake in shares of Nautilus Biotechnology by 4.9% in the first quarter. State Street Corp now owns 185,955 shares of the company’s stock worth $807,000 after purchasing an additional 8,755 shares in the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in shares of Nautilus Biotechnology by 67.5% in the fourth quarter. Qube Research & Technologies Ltd now owns 25,166 shares of the company’s stock worth $130,000 after purchasing an additional 10,138 shares in the last quarter. Hedge funds and other institutional investors own 47.89% of the company’s stock.

Nautilus Biotechnology Company Profile (Get Rating)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

Featured Stories